Skip to main content
Fig. 8 | Stem Cell Research & Therapy

Fig. 8

From: A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Fig. 8

Diabetic patients with CTLI improved their quality of life after the treatment with auto-BM-MNC or allo-WJ-MSCs. A EQ-5D profile of the participants showed statistically significant differences among auto-BM-MNC, allo-WJ-MSC, and placebo groups, before and after treatment. B The self-assessed measure of overall health (EQ-VAS) showed improvements in patients’ health problems from treatment. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512